SAN DIEGO — Mirador Therapeutics entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting anti-C5a antibody being developed for inflammatory vascular diseases.
The agreement gives Mirador exclusive rights to develop, manufacture and commercialize KP-301 across all indications. Kira will receive $12 million upfront and is eligible for additional development and sales milestone payments.
Mirador plans to initially develop KP-301 for ANCA-associated vasculitis, or AAV, a serious autoimmune disease involving inflammation and damage to small blood vessels.
The clinical-stage precision medicine company expects to begin a Phase 1 study by the end of 2026, followed by a Phase 2 AAV study during the first half of 2027. Mirador also plans to evaluate KP-301 as a monotherapy and in combination regimens for other inflammatory diseases.
KP-301 is designed to block C5a, a protein involved in complement-driven inflammation, and prevent signaling through the C5a receptor. The antibody incorporates pH-dependent target binding and antibody-recycling technology intended to provide sustained activity with less frequent dosing.
“Our strategy is disciplined: We take on big problems in I&I and pair each program with the modality most likely to succeed for patients. KP-301 is a textbook example of that thesis,” said Mark C. McKenna, Chairman and Chief Executive Officer of Mirador. “The biology of complement-driven vascular inflammation is well established, yet significant unmet need remains. KP-301 gives us the opportunity to deliver the benefit of C5a signaling inhibition through a differentiated, long-acting antibody, and it expands our portfolio into inflammatory vascular disease, where the science, the modality and the unmet need clearly align.”
Mirador said C5a and C5a receptor inhibition have demonstrated clinical benefits in AAV, but patients still need additional treatments with favorable safety, tolerability and dosing profiles.
The addition of KP-301 expands Mirador’s portfolio of treatments for immune-mediated inflammatory and fibrotic diseases.
The company plans to use its Mirador360 precision-development platform to support target validation, patient selection and indication prioritization. The platform draws on more than 2.5 million molecular profiles across immune-mediated diseases.
Mirador expects several clinical readouts from its broader immunology and inflammation portfolio by the end of 2027.
